Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intellectual Property

Set Alert for Intellectual Property

Dr Reddy’s Eyes Generic Revlimid Exclusivity With ANDA Approval

With Natco poised to debut the first batch of Revlimid generics in the US in March next year, fellow Indian ANDA sponsor Dr Reddy’s Laboratories has secured its own approval from the FDA for two strengths of the blockbuster multiple myeloma treatment.

Generic Drugs Approvals

Zydus Knocked Back On Farxiga In US As Brand Continues To Grow

Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.

Generic Drugs Companies

Zentiva Reveals Progress On Sitagliptin

Zentiva’s Zent2U B2B unit has reported progress on a bioequivalence study for its sitagliptin tablets, indicating that its version will be ready for day-one entry in Europe. The development comes shortly after Zent2U announced the successful completion of a sertraline study.

Generic Drugs Europe

Xbrane Secures Patents For Low-Cost Biosimilar Production

Xbrane Biopharma has celebrated after being granted two Swedish patents covering its “high-yield” protein expression platform that the biosimilars specialist expects to act as the basis for international applications.

Intellectual Property Biosimilars

Padagis Starts Life Post-Perrigo With Eucrisa Challenge

Padagis, the former Perrigo Rx business that was acquired by Altaris in July, has seen litigation initiated by Eucrisa originator Anacor over its Paragraph IV ANDA filing for crisaborole 2% ointment.

Strategy Intellectual Property

MPP Finds Three More Partners On Key Hepatitis C Treatment

The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

Deals Intellectual Property

Alvotech Sees AbbVie’s Humira Trade Secrets Case Thrown Out In US

One part of a multi-pronged attack launched by AbbVie against Alvotech over the company’s proposed Humira (adalimumab) biosimilar has fallen, with a US district court stating that AbbVie’s US trade secrets lawsuit should be dismissed because it lacks a form of jurisdiction.

Biosimilars Legal Issues

ANDA Sponsors Fail To Knock Out Trintellix Active Ingredient Patent

Danish originator Lundbeck says it is “unthinkable” that proposed generic versions of its Trintellix treatment for major depressive disorder will find a way to the US market before 2027 following a US district court decision.

Generic Drugs Intellectual Property

European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform

The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.

Europe Legislation
See All